Seer, Inc.
NNASDAQ:SEERCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Omid C. Farokhzad
- Full Time Employees
- 124
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 3800 Bridge Parkway Redwood City CA United States 94065
- IPO Date
- Dec 4, 2020
- CIK
- 0001726445
- Website
- seer.bio
- Similar Companies
- Business
- Seer, Inc. is a biotechnology company that develops and commercializes innovative proteomics solutions designed to decode the biology of the proteome. Its core product is the Proteograph Product Suite, an integrated solution consisting of proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software that enables unbiased, deep, rapid, and scalable proteomic analysis across complex biological samples. The Proteograph platform provides high-throughput access to proteins and peptides, capturing molecular information including protein variants, and is marketed primarily for research use in academic institutions, life sciences, biopharmaceutical, and biotechnology sectors. Seer operates globally with a presence in the United States, China, Australia, Eastern Europe, Israel, Japan, and South Africa. Founded in 2017 and headquartered in Redwood City, California, Seer has positioned itself as a leader in transformative proteomics technology. Recent major developments include the launch of new product applications for the Proteograph XT workflow specifically tailored for cell lysis proteomics, unlocking deeper intracellular proteomics capabilities. The company has also significantly increased instrument shipments in 2025, nearly tripling shipments in the first nine months compared to all of 2024, reflecting strong market demand. Seer expanded its strategic partnership with Thermo Fisher Scientific to accelerate adoption of the Proteograph Product Suite and continues to foster collaborations with leading service providers to broaden access to unbiased, deep proteomics at scale. Financially, Seer reported approximately $300 million in cash and investments as of late 2024 and projects revenue growth of around 24% for 2025, driven by product innovation, user base expansion, and increasing large-cohort studies in proteomics research. Seer targets proteomics and genomics markets offering research tools for biological discovery and biomarker identification. Its Proteograph platform integrates consumables, instrumentation, and analytical software to support scalable proteomic workflows compatible with widely used laboratory instruments. Seer’s strategic focus on external validation, technological innovation, and collaborative partnerships underscores its commitment to advancing proteomics for scientific research advancement worldwide. This comprehensive approach to proteomics and recent advancements in product applications, strategic partnerships, and market expansion emphasize Seer’s evolving leadership in life sciences and biotechnology sectors. Headquartered in Redwood City, California, Seer operates primarily in the United States with international reach in key global biotech markets. The company went public in 2020 and continues to grow its footprint through technology commercialization and service alliances. The CEO is Omid Farokhzad, who leads the company in driving adoption of its Proteograph technology platform.
Company News
Seer Secures Key Victory in ITC Patent Dispute as Investigative Staff Backs All Requested Remedies Against Nanomics
Radoff-JEC Group Issues Open Letter Condemning Seer's Unexplained and Seemingly Illogical Decision to Remain a Public Company
Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Seer to Report Third Quarter 2026 Financial Results on November 10, 2026
Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
Seer Announces CFO Transition
Seer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale
Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.'s Board of Directors
Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers
Seer Q2 Earnings Call Highlights
Seer, Inc. (SEER) Q2 2026 Earnings Call Transcript
Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook
Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference
Seer to Report Second Quarter 2026 Financial Results on August 11, 2026
SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law
SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law
Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.
SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law